C Lebbé1, J S Weber2, M Maio3, B Neyns4, K Harmankaya5, O Hamid6, S J O'Day7, C Konto8, L Cykowski8, M B McHenry9, J D Wolchok10. 1. Department of Dermatology, APHP, CIC, U976 Hôpital Saint-Louis University Paris Diderot, Paris, France. Electronic address: celeste.lebbe@sls.aphp.fr. 2. Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA. 3. Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy. 4. Department of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium. 5. Department of Dermatology, Medical University of Vienna, Vienna, Austria. 6. Melanoma Therapeutics, Translational Research and Immunotherapy, The Angeles Clinic and Research Institute, Los Angeles. 7. Los Angeles Skin Cancer Institute at Beverly Hills Cancer Center, Beverly Hills. 8. Global Clinical Research. 9. Global Biometric Sciences, Bristol-Myers Squibb Company, Wallingford. 10. Ludwig Center for Cancer Immunotherapy, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
Abstract
BACKGROUND: This report provides a survival update at a follow-up of >5 years (5.5-6 years) for patients with advanced melanoma who previously received ipilimumab in phase II clinical trials. Safety and efficacy data following ipilimumab retreatment are also reported. PATIENTS AND METHODS: Patients who previously received ipilimumab 0.3, 3, or 10 mg/kg in one of six phase II trials (CA184-004, CA184-007, CA184-008, CA184-022, MDX010-08, and MDX010-15) were eligible to enroll in the companion study, CA184-025. Upon enrollment, patients initially received ipilimumab retreatment, extended maintenance therapy, or were followed for survival only. Overall survival (OS) rates were evaluated in patients from studies CA184-004, CA184-007, CA184-008, and CA184-022. Safety and best overall response during ipilimumab retreatment at 10 mg/kg were assessed in study CA184-025. RESULTS: Five-year OS rates for previously treated patients who received ipilimumab induction at 0.3, 3, or 10 mg/kg were 12.3%, 12.3%-16.5%, and 15.5%-28.4%, respectively. Five-year OS rates for treatment-naive patients who received ipilimumab induction at 3 or 10 mg/kg were 26.8% and 21.4%-49.5%, respectively. Little to no change in OS was observed from year 5 up to year 6. The objective response rate among retreated patients was 23%. Grade 3/4 immune-related adverse events occurred in 25%, 5.9%, and 13.2% of retreated patients who initially received ipilimumab 0.3, 3, and 10 mg/kg, with the most common being observed in the skin (4.2%, 2.9%, 3.8%) and gastrointestinal tract (12.5%, 2.9%, 3.8%), respectively. CONCLUSIONS: At a follow-up of 5-6 years, ipilimumab continues to demonstrate durable, long-term survival in a proportion of patients with advanced melanoma. In some patients, ipilimumab retreatment can re-establish disease control with a safety profile that is comparable with that observed during ipilimumab induction. Further studies are needed to determine the contribution of ipilimumab retreatment to OS. CLINICALTRIALSGOV: NCT00162123.
BACKGROUND: This report provides a survival update at a follow-up of >5 years (5.5-6 years) for patients with advanced melanoma who previously received ipilimumab in phase II clinical trials. Safety and efficacy data following ipilimumab retreatment are also reported. PATIENTS AND METHODS: Patients who previously received ipilimumab 0.3, 3, or 10 mg/kg in one of six phase II trials (CA184-004, CA184-007, CA184-008, CA184-022, MDX010-08, and MDX010-15) were eligible to enroll in the companion study, CA184-025. Upon enrollment, patients initially received ipilimumab retreatment, extended maintenance therapy, or were followed for survival only. Overall survival (OS) rates were evaluated in patients from studies CA184-004, CA184-007, CA184-008, and CA184-022. Safety and best overall response during ipilimumab retreatment at 10 mg/kg were assessed in study CA184-025. RESULTS: Five-year OS rates for previously treated patients who received ipilimumab induction at 0.3, 3, or 10 mg/kg were 12.3%, 12.3%-16.5%, and 15.5%-28.4%, respectively. Five-year OS rates for treatment-naive patients who received ipilimumab induction at 3 or 10 mg/kg were 26.8% and 21.4%-49.5%, respectively. Little to no change in OS was observed from year 5 up to year 6. The objective response rate among retreated patients was 23%. Grade 3/4 immune-related adverse events occurred in 25%, 5.9%, and 13.2% of retreated patients who initially received ipilimumab 0.3, 3, and 10 mg/kg, with the most common being observed in the skin (4.2%, 2.9%, 3.8%) and gastrointestinal tract (12.5%, 2.9%, 3.8%), respectively. CONCLUSIONS: At a follow-up of 5-6 years, ipilimumab continues to demonstrate durable, long-term survival in a proportion of patients with advanced melanoma. In some patients, ipilimumab retreatment can re-establish disease control with a safety profile that is comparable with that observed during ipilimumab induction. Further studies are needed to determine the contribution of ipilimumab retreatment to OS. CLINICALTRIALSGOV: NCT00162123.
Authors: Peter A Prieto; James C Yang; Richard M Sherry; Marybeth S Hughes; Udai S Kammula; Donald E White; Catherine L Levy; Steven A Rosenberg; Giao Q Phan Journal: Clin Cancer Res Date: 2012-01-23 Impact factor: 12.531
Authors: F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba Journal: N Engl J Med Date: 2010-06-05 Impact factor: 91.245
Authors: Jedd D Wolchok; Bart Neyns; Gerald Linette; Sylvie Negrier; Jose Lutzky; Luc Thomas; William Waterfield; Dirk Schadendorf; Michael Smylie; Troy Guthrie; Jean-Jacques Grob; Jason Chesney; Kevin Chin; Kun Chen; Axel Hoos; Steven J O'Day; Celeste Lebbé Journal: Lancet Oncol Date: 2009-12-08 Impact factor: 41.316
Authors: Caroline Robert; Dirk Schadendorf; Marianne Messina; F Stephen Hodi; Steven O'Day Journal: Clin Cancer Res Date: 2013-02-26 Impact factor: 12.531
Authors: Jeffrey Weber; John A Thompson; Omid Hamid; David Minor; Asim Amin; Ilan Ron; Ruggero Ridolfi; Hazem Assi; Anthony Maraveyas; David Berman; Jonathan Siegel; Steven J O'Day Journal: Clin Cancer Res Date: 2009-08-11 Impact factor: 12.531
Authors: V Chiarion-Sileni; J Pigozzo; P A Ascierto; E Simeone; M Maio; L Calabrò; P Marchetti; F De Galitiis; A Testori; P F Ferrucci; P Queirolo; F Spagnolo; P Quaglino; F Carnevale Schianca; M Mandalà; L Di Guardo; M Del Vecchio Journal: Br J Cancer Date: 2014-03-11 Impact factor: 7.640
Authors: Evan M Hersh; Steven J O'Day; John Powderly; Khuda D Khan; Anna C Pavlick; Lee D Cranmer; Wolfram E Samlowski; Geoffrey M Nichol; Michael J Yellin; Jeffrey S Weber Journal: Invest New Drugs Date: 2010-01-16 Impact factor: 3.651
Authors: Jedd D Wolchok; F Stephen Hodi; Jeffrey S Weber; James P Allison; Walter J Urba; Caroline Robert; Steven J O'Day; Axel Hoos; Rachel Humphrey; David M Berman; Nils Lonberg; Alan J Korman Journal: Ann N Y Acad Sci Date: 2013-06-17 Impact factor: 5.691
Authors: Tiffany R Hodges; Sherise D Ferguson; Hillary G Caruso; Gary Kohanbash; Shouhao Zhou; Timothy F Cloughesy; Mitchel S Berger; George H Poste; Mustafa Khasraw; Sujuan Ba; Tao Jiang; Tom Mikkelson; W K Alfred Yung; John F de Groot; Howard Fine; Lewis C Cantley; Ingo K Mellinghoff; Duane A Mitchell; Hideho Okada; Amy B Heimberger Journal: Oncoimmunology Date: 2016-02-18 Impact factor: 8.110
Authors: Liudmila V Fedorova; Kirill V Lepik; Natalia B Mikhailova; Elena V Kondakova; Yuri R Zalyalov; Vadim V Baykov; Elena V Babenko; Andrey V Kozlov; Ivan S Moiseev; Boris V Afanasyev Journal: Ann Hematol Date: 2021-02-02 Impact factor: 3.673
Authors: Alexandre Doussot; Charlée Nardin; Haruyuki Takaki; Tess D Litchman; Michael I D'Angelica; William R Jarnagin; Michael A Postow; Joseph P Erinjeri; T Peter Kingham Journal: J Surg Oncol Date: 2015-06-12 Impact factor: 3.454
Authors: Allison Betof Warner; Jessica S Palmer; Alexander N Shoushtari; Debra A Goldman; Katherine S Panageas; Sara A Hayes; Raazi Bajwa; Parisa Momtaz; Margaret K Callahan; Jedd D Wolchok; Michael A Postow; Paul B Chapman Journal: J Clin Oncol Date: 2020-02-13 Impact factor: 44.544
Authors: Zeynep Eroglu; Dae Won Kim; Xiaoyan Wang; Luis H Camacho; Bartosz Chmielowski; Elizabeth Seja; Arturo Villanueva; Kathleen Ruchalski; John A Glaspy; Kevin B Kim; Wen-Jen Hwu; Antoni Ribas Journal: Eur J Cancer Date: 2015-09-10 Impact factor: 9.162